Yappli, Inc. (TYO:4168)

Theseus Pharmaceuticals Income Statement

Financials in millions JPY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	5,603	5,511	4,864	4,142	3,263	2,390
Revenue Growth (YoY)	11.75%	13.30%	17.43%	26.94%	36.53%	38.87%
Cost of Revenue	1,909	1,867	1,508	1,391	1,062	1,018
Gross Profit	3,694	3,644	3,356	2,751	2,201	1,372
Selling, General & Admin	2,829	2,820	2,730	3,511	3,076	1,907
Research & Development	250	250	319	-	-	-
Operating Expenses	3,102	3,093	3,091	3,570	3,130	1,962
Operating Income	592	551	265	-819	-929	-590
Interest Expense	-7	-6	-5	-4	-2	-6
Other Non Operating Income (Expenses)	4	3	-6	-3	-	-32
EBT Excluding Unusual Items	589	548	254	-826	-931	-628
Other Unusual Items	-	-	-530	-107	-	-
Pretax Income	589	548	-276	-933	-931	-628
Income Tax Expense	-22	-200	-202	8	8	4
Net Income	611	748	-74	-941	-939	-632
Net Income to Common	611	748	-74	-941	-939	-632
Shares Outstanding (Basic)	13	13	13	13	12	9
Shares Outstanding (Diluted)	13	13	13	13	12	9
Shares Change (YoY)	1.30%	2.21%	1.11%	2.54%	35.17%	21.41%
EPS (Basic)	47.17	57.71	-5.82	-74.86	-76.60	-69.68
EPS (Diluted)	47.17	57.58	-5.82	-74.86	-76.60	-69.68
Free Cash Flow	-	352	-161	-946	-928	-578
Free Cash Flow Per Share	-	27.10	-12.67	-75.25	-75.70	-63.73
Gross Margin	65.93%	66.12%	69.00%	66.42%	67.45%	57.41%
Operating Margin	10.57%	10.00%	5.45%	-19.77%	-28.47%	-24.69%
Profit Margin	10.90%	13.57%	-1.52%	-22.72%	-28.78%	-26.44%
Free Cash Flow Margin	-	6.39%	-3.31%	-22.84%	-28.44%	-24.18%
EBITDA	609.25	575	316	-757	-868	-532
EBITDA Margin	10.87%	10.43%	6.50%	-18.28%	-26.60%	-22.26%
D&A For EBITDA	17.25	24	51	62	61	58
EBIT	592	551	265	-819	-929	-590
EBIT Margin	10.57%	10.00%	5.45%	-19.77%	-28.47%	-24.69%
Advertising Expenses	-	894	956	1,382	1,118	700

Updated Feb 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.